Lifecore Biomedical (LFCR) Competitors

$4.54 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

LFCR vs. ZVRA, TLRY, SPRY, CRMD, and OVID

Should you buy Lifecore Biomedical stock or one of its competitors? Lifecore Biomedical's main competitors and comparable companies include Zevra Therapeutics (ZVRA), Tilray Brands (TLRY), ARS Pharmaceuticals (SPRY), CorMedix (CRMD), and Ovid Therapeutics (OVID). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lifecore Biomedical compare to Zevra Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Zevra Therapeutics has a net margin of 42.82% compared to Lifecore Biomedical's net margin of -29.93%. Zevra Therapeutics' return on equity of 54.54% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Zevra Therapeutics	42.82%	54.54%	34.15%

Lifecore Biomedical currently has a consensus price target of $6.50, indicating a potential upside of 43.17%. Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 134.80%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
Zevra Therapeutics	$136.07M	5.05	$83.23M	$0.92	12.57

Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Zevra Therapeutics had 4 more articles in the media than Lifecore Biomedical. MarketBeat recorded 5 mentions for Zevra Therapeutics and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.92 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Zevra Therapeutics	Positive

Summary

Zevra Therapeutics beats Lifecore Biomedical on 12 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Lifecore Biomedical has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$210.48M	2.97	-$121.40M	-$1.08	N/A
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A

Tilray Brands presently has a consensus price target of $8.00, suggesting a potential upside of 74.29%. Lifecore Biomedical has a consensus price target of $6.50, suggesting a potential upside of 43.17%. Given Tilray Brands' stronger consensus rating and higher probable upside, research analysts clearly believe Tilray Brands is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tilray Brands had 13 more articles in the media than Lifecore Biomedical. MarketBeat recorded 14 mentions for Tilray Brands and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Tilray Brands' score of 0.56 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Tilray Brands	Positive
Lifecore Biomedical	Very Positive

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tilray Brands has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Tilray Brands has a net margin of -13.11% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Summary

Tilray Brands beats Lifecore Biomedical on 10 of the 17 factors compared between the two stocks.

How does Lifecore Biomedical compare to ARS Pharmaceuticals?

Lifecore Biomedical (NASDAQ:LFCR) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Lifecore Biomedical presently has a consensus price target of $6.50, suggesting a potential upside of 43.17%. ARS Pharmaceuticals has a consensus price target of $28.20, suggesting a potential upside of 378.78%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lifecore Biomedical has a net margin of -29.93% compared to ARS Pharmaceuticals' net margin of -184.24%. Lifecore Biomedical's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, ARS Pharmaceuticals had 21 more articles in the media than Lifecore Biomedical. MarketBeat recorded 22 mentions for ARS Pharmaceuticals and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat ARS Pharmaceuticals' score of 0.22 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
ARS Pharmaceuticals	Neutral

Lifecore Biomedical has higher revenue and earnings than ARS Pharmaceuticals. Lifecore Biomedical is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
ARS Pharmaceuticals	$84.28M	6.95	-$171.30M	-$2.18	N/A

Summary

Lifecore Biomedical beats ARS Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Lifecore Biomedical compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

CorMedix presently has a consensus target price of $15.00, suggesting a potential upside of 80.72%. Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 43.17%. Given CorMedix's stronger consensus rating and higher probable upside, research analysts clearly believe CorMedix is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

CorMedix has higher revenue and earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.08	$163.05M	$2.14	3.88
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A

CorMedix has a net margin of 40.49% compared to Lifecore Biomedical's net margin of -29.93%. CorMedix's return on equity of 40.52% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Lifecore Biomedical	-29.93%	N/A	-16.16%

In the previous week, CorMedix and CorMedix both had 1 articles in the media. CorMedix's average media sentiment score of 1.89 equaled Lifecore Biomedical'saverage media sentiment score.

Company	Overall Sentiment
CorMedix	Very Positive
Lifecore Biomedical	Very Positive

34.2% of CorMedix shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CorMedix beats Lifecore Biomedical on 12 of the 14 factors compared between the two stocks.

How does Lifecore Biomedical compare to Ovid Therapeutics?

Lifecore Biomedical (NASDAQ:LFCR) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Lifecore Biomedical presently has a consensus price target of $6.50, indicating a potential upside of 43.17%. Ovid Therapeutics has a consensus price target of $5.71, indicating a potential upside of 104.08%. Given Ovid Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Ovid Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
Ovid Therapeutics	$7.25M	75.43	-$17.41M	-$0.31	N/A

In the previous week, Ovid Therapeutics had 2 more articles in the media than Lifecore Biomedical. MarketBeat recorded 3 mentions for Ovid Therapeutics and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Ovid Therapeutics' score of 1.31 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Ovid Therapeutics	Positive

Lifecore Biomedical has a net margin of -29.93% compared to Ovid Therapeutics' net margin of -240.11%. Lifecore Biomedical's return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Lifecore Biomedical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market.

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 7.0% of Ovid Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Lifecore Biomedical beats Ovid Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$171.85M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-4.24	787.65	273.16	25.45
Price / Sales	1.33	792.89	605.01	76.63
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	-5.04	11.97	12.98	6.14
Net Income	-$40.50M	$2.83B	$3.48B	$348.86M
7 Day Performance	N/A	0.39%	0.13%	-0.80%
1 Month Performance	4.13%	5.34%	7.08%	4.13%
1 Year Performance	-40.34%	6.05%	24.67%	15.17%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	2.4722 of 5 stars	$4.54 flat	$6.50 +43.2%	-40.3%	$171.85M	$128.87M	N/A	690	Positive News Analyst Downgrade Gap Down
ZVRA Zevra Therapeutics	4.624 of 5 stars	$11.57 +0.3%	$27.14 +134.6%	+27.5%	$672.22M	$106.47M	12.58	20
TLRY Tilray Brands	4.0303 of 5 stars	$4.47 -0.2%	$11.00 +146.1%	-66.7%	$636.07M	$915.45M	N/A	3,595
SPRY ARS Pharmaceuticals	2.3885 of 5 stars	$6.30 +1.0%	$28.20 +347.6%	-49.3%	$619.65M	$116.93M	N/A	90	Trending News
CRMD CorMedix	2.5144 of 5 stars	$8.17 +6.5%	$15.00 +83.6%	-44.0%	$597.83M	$457.20M	3.82	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ZVRA, TLRY, SPRY, CRMD, and OVID

How does Lifecore Biomedical compare to Zevra Therapeutics?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Summary

How does Lifecore Biomedical compare to ARS Pharmaceuticals?

Summary

How does Lifecore Biomedical compare to CorMedix?

Summary

How does Lifecore Biomedical compare to Ovid Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. ZVRA, TLRY, SPRY, CRMD, and OVID

How does Lifecore Biomedical compare to Zevra Therapeutics?

Is LFCR or ZVRA more profitable?

Do analysts recommend LFCR or ZVRA?

Do insiders and institutionals believe in LFCR or ZVRA?

Which has higher earnings and valuation, LFCR or ZVRA?

Which has more volatility & risk, LFCR or ZVRA?

Does the media favor LFCR or ZVRA?

Summary

How does Lifecore Biomedical compare to Tilray Brands?

Which has stronger valuation and earnings, TLRY or LFCR?

Do analysts rate TLRY or LFCR?

Does the media refer more to TLRY or LFCR?

Do institutionals & insiders have more ownership in TLRY or LFCR?

Which has more risk & volatility, TLRY or LFCR?

Is TLRY or LFCR more profitable?

Summary

How does Lifecore Biomedical compare to ARS Pharmaceuticals?

Which has more risk and volatility, LFCR or SPRY?

Do analysts rate LFCR or SPRY?

Is LFCR or SPRY more profitable?

Do institutionals and insiders have more ownership in LFCR or SPRY?

Does the media refer more to LFCR or SPRY?

Which has higher valuation & earnings, LFCR or SPRY?

Summary

How does Lifecore Biomedical compare to CorMedix?

Do analysts recommend CRMD or LFCR?

Which has more volatility and risk, CRMD or LFCR?

Which has higher valuation & earnings, CRMD or LFCR?

Is CRMD or LFCR more profitable?

Does the media favor CRMD or LFCR?

Do insiders & institutionals have more ownership in CRMD or LFCR?

Summary

How does Lifecore Biomedical compare to Ovid Therapeutics?

Do analysts recommend LFCR or OVID?

Which has higher earnings and valuation, LFCR or OVID?

Does the media refer more to LFCR or OVID?

Is LFCR or OVID more profitable?

Which has more volatility & risk, LFCR or OVID?

Do institutionals and insiders believe in LFCR or OVID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools